Johnson & Johnson announced a first-of-its-kind partnership with the Division of Medical Ethics at the NYU School of Medicine that enlists a third party to review requests made to the Janssen Pharmaceutical Companies for compassionate use of its investigational medicines. A pilot program will focus on a single Janssen investigational medicine and, if successful, will become a model that will be applicable more broadly across Johnson & Johnson.

The company will obtain independent advice, further ensuring that the evaluation of requests for investigational medicines prior to their approval by the U.S. FDA or other global health authorities are treated in the most fair and ethical manner.

The NYU School of Medicine will establish the Compassionate-Use Advisory Committee (CompAC), an external group of 10 internationally recognized medical experts, bioethicists and patient representatives to pilot the new approach.